Allena Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar...


3. Net Loss per Share


Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares , including options to purchase common stock, restricted stock units, common stock issuable upon the conversion of outstanding debt and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.


Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):


 















































































































































 


 


Three Months Ended June 30,


 


 


Six Months Ended June 30,


 


 


 


2021


 


 


2020


 


 


2021


 


 


2020


 


Numerator:


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Net loss


 


$


(13,972


)


 


$


(6,976


)


 


$


(25,608


)


 


$


(14,561


)


Net loss attributable to common stockholders


 


$


(13,972


)


 


$


(6,976


)


 


$


(25,608


)


 


$


(14,561


)


Denominator:


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Weighted-average common shares—basic and diluted


 


 


57,932,389


 


 


 


26,878,962


 


 


 


56,484,811


 


 


 


25,808,043


 


Net loss per share attributable to common


   stockholders—basic and diluted


 


$


(0.24


)


 


$


(0.26


)


 


$


(0.45


)


 


$


(0.56


)


 


The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):


 











































































 


 


Six Months Ended June 30,


 


 


 


2021


 


 


2020


 


Stock options


 


 


7,091,757


 


 


 


3,766,567


 


Restricted stock units


 


 


372,166


 


 


 


553,468


 


Common stock issuable upon conversion of outstanding debt


 


 


2,439,024


 


 


 



 


Warrants


 


 


9,040


 


 


 


9,040


 


Total


 


 


9,911,987


 


 


 


4,329,075


 


 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Allena Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Submission of Matters to a Vote of Security - Aug. 4, 2022
Allena Pharmaceuticals: Confidential, For Use Of The Commission Only (As Permitted By Rule - July 13, 2022
Allena Pharmaceuticals: Confidential, For Use Of The Commission Only (As Permitted By Rule - July 12, 2022
Allena Pharmaceuticals: New Meeting Date And New Record Date For - July 12, 2022

Auto Refresh

Feedback